LT2392336T - 24-norudca, skirta autoimuninio hepatito gydymui - Google Patents

24-norudca, skirta autoimuninio hepatito gydymui

Info

Publication number
LT2392336T
LT2392336T LTEP11176271.2T LT11176271T LT2392336T LT 2392336 T LT2392336 T LT 2392336T LT 11176271 T LT11176271 T LT 11176271T LT 2392336 T LT2392336 T LT 2392336T
Authority
LT
Lithuania
Prior art keywords
norudca
autoimmune hepatitis
treating autoimmune
treating
hepatitis
Prior art date
Application number
LTEP11176271.2T
Other languages
English (en)
Inventor
Michael Trauner
Alan Hofmann
Peter Fickert
Original Assignee
Medizinische Universität Graz
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medizinische Universität Graz filed Critical Medizinische Universität Graz
Publication of LT2392336T publication Critical patent/LT2392336T/lt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Oscillators With Electromechanical Resonators (AREA)
  • Ultra Sonic Daignosis Equipment (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
LTEP11176271.2T 2005-05-12 2005-05-12 24-norudca, skirta autoimuninio hepatito gydymui LT2392336T (lt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP11176271.2A EP2392336B1 (en) 2005-05-12 2005-05-12 24-norUDCA for treating autoimmune hepatitis
PCT/EP2005/052178 WO2006119803A1 (en) 2005-05-12 2005-05-12 USE OF 24-nor-UDCA

Publications (1)

Publication Number Publication Date
LT2392336T true LT2392336T (lt) 2016-10-10

Family

ID=35457032

Family Applications (1)

Application Number Title Priority Date Filing Date
LTEP11176271.2T LT2392336T (lt) 2005-05-12 2005-05-12 24-norudca, skirta autoimuninio hepatito gydymui

Country Status (18)

Country Link
US (1) US8951995B2 (lt)
EP (4) EP2392336B1 (lt)
AU (1) AU2005331734B2 (lt)
CY (4) CY1116831T1 (lt)
DK (4) DK2392336T3 (lt)
EA (1) EA014077B1 (lt)
ES (4) ES2547127T3 (lt)
HK (1) HK1161122A1 (lt)
HR (3) HRP20150949T1 (lt)
HU (4) HUE025184T2 (lt)
LT (1) LT2392336T (lt)
ME (3) ME02544B (lt)
NO (1) NO340318B1 (lt)
PL (4) PL2392336T3 (lt)
PT (3) PT2392335E (lt)
RS (3) RS55180B1 (lt)
SI (4) SI2392337T1 (lt)
WO (1) WO2006119803A1 (lt)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080275030A1 (en) 2007-01-19 2008-11-06 Sveinbjorn Gizurarson Methods and Compositions for the Delivery of a Therapeutic Agent
TR201901012T4 (tr) * 2007-07-25 2019-02-21 Univ Graz Medizinische Arteriosklerozun tedavisinde nor-safra asitlerinin kullanımı.
EP2468762A1 (en) * 2010-11-30 2012-06-27 Dr. Falk Pharma Gmbh Optimized synthesis of pure, non-polymorphic, crystalline bile acids with defined particle size
EP3461485A1 (en) 2017-09-28 2019-04-03 Dr. Falk Pharma Gmbh Use of nor-ursodeoxycholic acid for reducing liver fat
GB201911821D0 (en) 2019-08-16 2019-10-02 Provost Fellows Found Scholars And The Other Members Of Board Of The College Of The Holy And Undivid Compounds for use in the treatment of liver disease
US11372809B2 (en) * 2019-09-27 2022-06-28 Oracle International Corporation System and method for providing correlated content organization in an enterprise content management system based on a training set
WO2021130232A1 (en) 2019-12-23 2021-07-01 Medizinische Universität Wien Bile acid derivatives in the medical intervention of anxieties and/or stress symptoms
WO2024023669A1 (en) * 2022-07-25 2024-02-01 Shilpa Medicare Limited Pharmaceutical compositions of nor-udca

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4892868A (en) 1984-08-17 1990-01-09 Gipharmex, S.P.A. Derivatives of biliary acids, process for the production thereof and corresponding pharmaceutical compositions
IT1229569B (it) * 1989-04-17 1991-09-04 Giuliani Spa Derivati di acidi biliari, loro preparazione e composizioni farmaceutiche che li contengono.
IT1255449B (it) 1992-06-30 1995-10-31 Fabio Berlati Uso di nor- e omo-derivati di acidi biliari come promotori di assorbimento di farmaci.
TW289020B (lt) 1993-05-08 1996-10-21 Hoechst Sktiengesellschaft
ITMI20012572A1 (it) 2001-12-06 2003-06-06 Istituto Biochimico Italiano Microgranuli di acido ursodesossicolico

Also Published As

Publication number Publication date
SI1890705T1 (sl) 2016-02-29
EP2392335A2 (en) 2011-12-07
CY1116831T1 (el) 2017-03-15
PT2392337E (pt) 2015-11-02
EP2392336B1 (en) 2016-06-22
CY1117174T1 (el) 2017-04-05
NO20076405L (no) 2008-02-11
HUE025184T2 (en) 2016-01-28
US8951995B2 (en) 2015-02-10
EP2392337B1 (en) 2015-07-29
WO2006119803A1 (en) 2006-11-16
EA014077B1 (ru) 2010-08-30
EP2392335B1 (en) 2015-06-24
RS54185B1 (en) 2015-12-31
SI2392337T1 (sl) 2015-10-30
ME02544B (me) 2017-02-20
EP1890705A1 (en) 2008-02-27
EP2392336A2 (en) 2011-12-07
AU2005331734A1 (en) 2006-11-16
ES2590333T3 (es) 2016-11-21
SI2392336T1 (sl) 2016-10-28
EA200702336A1 (ru) 2008-04-28
HRP20161197T1 (hr) 2016-11-04
ES2561614T3 (es) 2016-02-29
EP1890705B1 (en) 2015-11-11
EP2392336A3 (en) 2011-12-28
DK2392337T3 (en) 2015-09-28
CY1117959T1 (el) 2017-05-17
CY1116840T1 (el) 2017-03-15
ES2550204T3 (es) 2015-11-05
EP2392337A2 (en) 2011-12-07
HUE030010T2 (en) 2017-04-28
HRP20150949T1 (hr) 2015-12-04
ME02737B (me) 2015-12-31
NO340318B1 (no) 2017-03-27
HUE025409T2 (en) 2016-02-29
PL2392336T3 (pl) 2016-12-30
EP2392337A3 (en) 2012-01-04
ME02256B (me) 2015-12-31
SI2392335T1 (sl) 2015-10-30
HK1161122A1 (en) 2012-08-24
PT2392336T (pt) 2016-10-04
RS54140B1 (en) 2015-12-31
DK2392335T3 (en) 2015-06-29
US20090163459A1 (en) 2009-06-25
EP2392335A3 (en) 2011-12-28
PT2392335E (pt) 2015-10-06
PL2392337T3 (pl) 2015-12-31
AU2005331734B2 (en) 2012-04-19
HRP20151091T1 (hr) 2015-11-06
PL2392335T3 (pl) 2015-10-30
DK1890705T3 (en) 2016-02-01
PL1890705T3 (pl) 2016-05-31
ES2547127T3 (es) 2015-10-01
DK2392336T3 (en) 2016-09-05
HUE028336T2 (en) 2016-12-28
RS55180B1 (sr) 2017-01-31

Similar Documents

Publication Publication Date Title
IL180645A0 (en) Methods for treating hepatitis c
GB0514593D0 (en) Process
GB0523969D0 (en) Inductivwe component
GB0513866D0 (en) Process
GB0511460D0 (en) Process
GB0501730D0 (en) Process
GB0514698D0 (en) Process
GB0506788D0 (en) Process
PL2392336T3 (pl) 24-norUDCA do leczenia autoimmunologicznego zapalenia wątroby
GB0513978D0 (en) Process
GB0503694D0 (en) Process
ZA200701235B (en) Methods for treating hepatitis C
GB0501349D0 (en) Process
GB0501102D0 (en) Process
EP1915131A4 (en) PROCESS
GB0503528D0 (en) Process
GB0516155D0 (en) Process
GB0512662D0 (en) Process
GB0513680D0 (en) Biowaste treatment
GB0505200D0 (en) Process
GB0505221D0 (en) Process
GB0504079D0 (en) Process
GB0501254D0 (en) Process
GB0501100D0 (en) Process
GB0519735D0 (en) Biowaste treatment